Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন।
Indications
TRILEXA BEXICAP 100/62.5/25 MG is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and moderate to severe asthma in adult patients requiring triple therapy.
Pharmacology
This capsule combines three active substances: an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA). Together, they reduce airway inflammation, relax bronchial muscles, and improve breathing efficiency.
Dosage & Administration
The usual dosage is one capsule inhaled once daily using a compatible inhalation device. The capsule must not be swallowed. Follow the inhaler usage instructions carefully.
Interaction
May interact with systemic corticosteroids, beta-blockers, anticholinergics, and antifungal agents. Inform your physician about all concurrent medications.
Contraindications
Contraindicated in patients with known hypersensitivity to any of the components. Not intended for relief of acute bronchospasm.
Side Effects
Common side effects include throat irritation, headache, dry mouth, cough, and hoarseness. Rarely, patients may experience increased heart rate, anxiety, or tremors.
Pregnancy & Lactation
Should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Always consult a physician.
Precautions & Warnings
Caution is advised in patients with cardiovascular disease, diabetes, thyroid disorders, glaucoma, or urinary retention. Do not discontinue therapy abruptly.
Therapeutic Class
Triple combination inhaled therapy (ICS + LABA + LAMA)
Storage Conditions
Store in a cool and dry place below 30°C. Keep out of reach of children. Do not expose to direct sunlight or moisture.
.jpg)
 15050160.jpg)
 10025 100 MG 25 MG.jpg)
 30PCS.jpg)
 20025 20025.jpg)
 350ML.jpg)
.jpg)
 350ML.jpg)
 100 IU.jpg)
 400MG.jpg)
 100 IU.jpg)
 60 ML.jpg)
Change Language